EP Patent

EP1655029A1 — Medicinal compositions

Assigned to Kyowa Kirin Co Ltd · Expires 2006-05-10 · 20y expired

What this patent protects

The present invention provides pharmaceutical compositions, which are useful for treatment of depression and the like, and which comprises a compound having an adenosine A 2A receptor antagonistic activity such as (E) -8- (3, 4-dimethoxystyryl) - 1,3-diethyl-7-methyl-3,7-dihydro…

USPTO Abstract

The present invention provides pharmaceutical compositions, which are useful for treatment of depression and the like, and which comprises a compound having an adenosine A 2A receptor antagonistic activity such as (E) -8- (3, 4-dimethoxystyryl) - 1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof and an antidepressant drug (for example, a tricyclic antidepressant, a tetracyclic antidepressant, a selective serotonin reuptake inhibitor, a selective noradrenalin reuptake inhibitor, a dopamine reuptake inhibitor, a serotonin-noradrenalin reuptake inhibitor, a monoamine oxidase inhibitor, a 5-HT 2 antagonist or the like), and the like.

Drugs covered by this patent

Patent Metadata

Patent number
EP1655029A1
Jurisdiction
EP
Classification
Expires
2006-05-10
Drug substance claim
No
Drug product claim
No
Assignee
Kyowa Kirin Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.